DOCSLIB.ORG

Recovercf.Ie :// Hhps [email protected]

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Recovercf.Ie :// Hhps Info@Recovercf.Ie Real World Clinical Outcomes with Novel Modulator Therapy Combinations in people with Cystic Fibrosis (RECOVER) P. McNally 1, 2, E. McKone 3, 4, D. Cox 2, 4, B. Linnane 5, 6, M. Williamson 7, B. Elnazir 8, 9, D. Downey 10, 11, A. Reid 11, 12, A. Fleming 1, A. Jackson 13, B. Bourke 2, 4, A. Quittner 14, 15, J. Mainz 16, 17, H. Tiddens 18, F. Ratjen 19, 20, J. Davies 21, 22, on behalf of the RECOVER research team and collaborators 1Royal College of Surgeons, Ireland, Dublin, Ireland, 2Children's Health Ireland at Crumlin, Dublin 12, Ireland, 3St. Vincent's University Hospital, Dublin, Ireland, 4University College Dublin, Dublin, Ireland, 5University of Limerick, Limerick, Ireland, 6University Hospital Limerick, Limerick, Ireland, 7Children's Health Ireland at Temple Street, Dublin, Ireland, 8Children's Health Ireland at Tallaght, Dublin, Ireland, 9Trinity College Dublin, Dublin, Ireland, 10Belfast City Hospital, Belfast, United Kingdom, 11Belfast Health and Social Care Trust, Belfast, United Kingdom, 12Royal Belfast Hospital for Sick Children, Belfast, United Kingdom, 13Cystic Fibrosis Registry of Ireland, Dublin, Ireland, 14University of Miami, Miami, United States, 15Nicklaus Children's Hospital, Miami, United States, 16MHB Theodor Fontane, Brandenburg, Germany, 17Klinikum Westbrandenburg, Potsdam, Germany, 18Erasmus MC, Rotterdam, Netherlands, 19The Hospital for Sick Children (SickKids), Toronto, Canada, 20University of Toronto, Toronto, Canada, 21The Royal Brompton Hospital, London, United Kingdom, 22Imperial College London, London, United Kingdom INTRODUCTION RESULTS VISIT SCHEDULE Month 0 1 2 3 6 9 12 15 18 21 24 Group FF MF p value Sweat Chloride X X X X Recruitment (n) 70 37 NA at: Real world, post approval studies contribute Recruitment LCI X X X X X Age (SD) 19.26(1.1) 19.24(1.9) 0.99 significantly to the evidence surrounding the Spirometry-controlled CT X X X Female (%) 32(45.7) 18(48.6) 0.77 Recruitment commenced in October 2020. 113 PWCF Height / Weight / BMI X X X X X X X X X Presented impact of new treatments, including CFTR Sweat Chloride (SE) 77.7(2.4) 91.94(3.5) 0.003 have been recruited to the study to date with 6 FEV1 X X X X X X X X X modulators, but can be complex undertakings. ppFEV1 (SE) 82.9(1.9) 83.2(2.7) 0.94 withdrawals. The reason for withdrawals included Airway Sampling (Micro) X X X X X X X X X Elexacaftor-Tezacaftor-Ivacaftor (ETI) was LCI (SE) 11.96(0.71) 12.76(0.8) 0.46 removal of study consent, amended ETI dosage for Nasal Lavage X X X approved by EMA sooner than expected in FeNO (SE) 14.47(1.3) 12.97(1.7) 0.49 clinical reasons, discontinuation of ETI for medical FeNO X X X August 2020 during a global pandemic. Liver Function Testing X X X X X X BMI z score (SE) 0.14(0.10) 0.06(0.12) 0.64 reasons and pregnancy in one subject. Data on 107 Liver Ultrasound X X X Weight z score (SE) 0.1(0.11) 0.03(0.10) 0.68 PWCF is presented. Sputum Collection X X X X Height z score (SE) -0.1(0.14) -0.11(0.13) 0.96 Liver Examination X X X Table 1: Baseline characteristics of recruited participants. Stool Collection X X X X Study Challenges FF = homozygous for the F508del mutation, MF = heterozygous Blood Collection X X for F508del/minimum function mutation, ppFEV1 = percent AIM The COVID-19 pandemic introduced a number of Abdominal Symptom Score X X X X X X predicted FEV1, FeNo = Fraction of exhaled nitric oxide. challenges to the study. Accelerated approval for ETI in CFQ-R X X X X Pharmacy Records MPR X X X Baseline Data Europe meant that the study setup period was The Aim of RECOVER is to develop a deeper Adherence Questionnaire X X X X X X X X X foreshortened, and made more complex given the Baseline data from the currently recruited understanding of the impact of ETI in the lives MEMS Caps Reading X increased priority given by clinical sites, universities and Antibiotic Use X X X participants reveals no significant differences apart and health of people with CF in a real world ethics committees for COVID19 related projects. from lower sweat chloride levels in the FF group setting. RECOVER Design Enforced limitations on CF centre attendances and as the vast majority moved to ETI from a dual aerosol generating procedures impacted on recruitment The sampling schedule of RECOVER is designed to collect a combination CFTR modulator. and collection of samples and test results. Despite these comprehensive array of outcome measures on each study participant challenges acceptable levels of recruitment were seen. based around annual assessment and quarterly clinic attendance. Study Progress METHODS The main impact on data collection was in the area of Banking of biological samples (blood, sputum, stool, nasal lavage) Data collection is ongoing for the 12+ cohort and sputum sample collection. seeks to broaden the scope and reach of the research insights active planning is underway for the recruitment of achievable from the data. children to the 6-11 year old group. RECOVER, a multi-centre post-approval study examining the impact of ETI, and conducted in 8 clinical sites in Ireland and the UK over 2 years, will examine important outcomes in children and RECOVER SITES RECOVER COLLABORATORS ACKNOWLEDGEMENTSAKNOWLEDGEMENTS adults prescribed ETI. The study will be conducted in 2 phases in line with ETI approval: St Vincent’s UH Ed McKone We want to thank all of our study participants and parents for 12+ and 6-11. In addition to routine data their time, dedication and enthusiasm, the whole RECOVER collected as part of normal care, key RECOVER UH Limerick Barry Linnane study team, collaborators and staff at our clinical sites. Funding endpoints include lung clearance index (LCI), for RECOVER is from the Cystic Fibrosis Foundation, CF spirometry controlled CT scores, treatment Royal Brompton Jane Davies Ireland and the CF Trust. Supported by ECFS-CTN. adherence, GI symptoms and inflammation, liver disease markers, nasal inflammation and nitric CHI Crumlin Des Cox oxide metabolism. RECOVER is supported by the ECFS Clinical Trials Network, including the CHI Temple St Michael Williamson core sites for LCI and spirometry controlled CT. 2 - Cell Biology/Physiology/New Therapies/ClinicalTrials Paul McNally CHI Tallaght Basil Elnazir CONTACT INFORMATION We present the baseline data from the first Belfast City Damian Downey phase of the study – people with CF aged 12 ClinicalTrials.gov NCT04602468 years and above. Royal Children’s Alastair Reid [email protected] hhps://recovercf.ie P-042 ECFS2021.
Load more

Recommended publications
  • Therapeutic Potential for Coxibs-Nitric Oxide Releasing Hybrids in Cystic fibrosis
    European Journal of Medicinal Chemistry xxx (xxxx) xxx Contents lists available at ScienceDirect European Journal of Medicinal Chemistry journal homepage: http://www.elsevier.com/locate/ejmech Research paper Therapeutic potential for coxibs-nitric oxide releasing hybrids in cystic fibrosis Sara Consalvi a, Giovanna Poce a, Carla Ghelardini b, Lorenzo Di Cesare Mannelli b, Paola Patrignani c, Annalisa Bruno c, Maurizio Anzini d, Vincenzo Calderone e, * Alma Martelli e, Lara Testai e, Antonio Giordani f, Mariangela Biava a, a Department of Chemistry and Technologies of Drug, Sapienza University of Rome, Piazzale A. Moro 5, 00185, Rome, Italy b Department of Neuroscience, Psychology, Drug Research and Child Health, University of Florence, Via Schiff 6, Sesto Fiorentino, 50019, Florence, Italy c Department of Neuroscience, Imaging and Clinical Sciences, And Center for Advanced Studies and Technology (CAST), School of Medicine, G. D’Annunzio University, Chieti, Italy d Department of Biotechnology, Chemistry, And Pharmacy, DoE 2018-2022, University of Siena, 53100, Siena, Italy e Department of Pharmacy, University of Pisa, Via Bonanno 6, 56126, Pisa, Italy f Formerly Rottapharm at the Present Consultant, Italy article info abstract Article history: This review discusses the rational for further studies of COX-2 inhibitors-NO releaser hybrids (NO- Received 4 June 2020 Coxibs) in the pharmacological treatment of the airway inflammation in Cystic Fibrosis (CF). Our research Received in revised form group developed several classes of NO-Coxibs for the pharmacological treatment of arthritis, and among 27 October 2020 them several compounds showed an outstanding in vivo efficacy and good pharmacokinetic properties. Accepted 28 October 2020 The good antiinflammatory properties displayed by these compounds during the previous screening could, by itself, suggest appropriate candidates for further testing in CF.
    [Show full text]
  • Elexacaftor/Tezacaftor/Ivacaftor) P&T Approval Date 11/2019, 11/2020, 3/2021, 7/2021 Effective Date 9/1/2021; Oxford Only: 10/1/2021
    UnitedHealthcare Pharmacy Clinical Pharmacy Programs Program Number 2021 P 2180-4 Program Prior Authorization/Medical Necessity Medication Trikafta® (elexacaftor/tezacaftor/ivacaftor) P&T Approval Date 11/2019, 11/2020, 3/2021, 7/2021 Effective Date 9/1/2021; Oxford only: 10/1/2021 1. Background: Trikafta is a combination of elexacaftor, tezacaftor, and ivacaftor, indicated for the treatment of patients with cystic fibrosis (CF) age 6 years and older who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene or a mutation in the CFTR gene that is responsive based on in vitro data. If the patient’s genotype is unknown, an FDA-cleared CF mutation test should be used to confirm the presence of at least one F508del mutation or a mutation that is responsive based on in vitro data. Members will be required to meet the coverage criteria below. 2. Coverage Criteriaa: A. Initial Authorization 1. Trikafta will be approved based upon all of the following criteria: a. Diagnosis of cystic fibrosis (CF) -AND- b. Submission of laboratory results documenting that the patient has at least one of the following mutations in the CFTR gene: (1) F508del mutation (2) A mutation that is responsive based on in vitro data1* *List of CFTR gene mutations that are responsive to Trikafta 3141del9 E822K G1069R L967S R117L S912L 546insCTA F191V G1244E L997F R117P S945L A46D F311del G1249R L1077P R170H S977F © 2021 UnitedHealthcare Services, Inc. 1 A120T F311L G1349D L1324P R258G S1159F A234D F508C H139R L1335P R334L
    [Show full text]
  • Anatomical Classification Guidelines V2021 EPHMRA ANATOMICAL CLASSIFICATION GUIDELINES 2021
    EPHMRA ANATOMICAL CLASSIFICATION GUIDELINES 2021 Anatomical Classification Guidelines V2021 "The Anatomical Classification of Pharmaceutical Products has been developed and maintained by the European Pharmaceutical Marketing Research Association (EphMRA) and is therefore the intellectual property of this Association. EphMRA's Classification Committee prepares the guidelines for this classification system and takes care for new entries, changes and improvements in consultation with the product's manufacturer. The contents of the Anatomical Classification of Pharmaceutical Products remain the copyright to EphMRA. Permission for use need not be sought and no fee is required. We would appreciate, however, the acknowledgement of EphMRA Copyright in publications etc. Users of this classification system should keep in mind that Pharmaceutical markets can be segmented according to numerous criteria." © EphMRA 2021 Anatomical Classification Guidelines V2021 CONTENTS PAGE INTRODUCTION A ALIMENTARY TRACT AND METABOLISM 1 B BLOOD AND BLOOD FORMING ORGANS 28 C CARDIOVASCULAR SYSTEM 36 D DERMATOLOGICALS 51 G GENITO-URINARY SYSTEM AND SEX HORMONES 58 H SYSTEMIC HORMONAL PREPARATIONS (EXCLUDING SEX HORMONES) 68 J GENERAL ANTI-INFECTIVES SYSTEMIC 72 K HOSPITAL SOLUTIONS 88 L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS 96 M MUSCULO-SKELETAL SYSTEM 106 N NERVOUS SYSTEM 111 P PARASITOLOGY 122 R RESPIRATORY SYSTEM 124 S SENSORY ORGANS 136 T DIAGNOSTIC AGENTS 143 V VARIOUS 145 Anatomical Classification Guidelines V2021 INTRODUCTION The Anatomical Classification was initiated in 1971 by EphMRA. It has been developed jointly by Intellus/PBIRG and EphMRA. It is a subjective method of grouping certain pharmaceutical products and does not represent any particular market, as would be the case with any other classification system.
    [Show full text]
  • Discovery Awaits You at the 81ST Scientific Sessions
    VIRTUAL | JUNE 25–29, 2021 Discovery awaits you at the ST 81 Scientific Sessions Final Program scientificsessions.diabetes.org #ADA2021 THE RIGHT SOLUTION AT THE RIGHT TIME View The Scientific Sessions Closed-Loop Increases Time-in-Range Glycemic outcomes of new InPen™ Durable insulin pumps vs. multiple daily in Older Adults with Type 1 Diabetes smart insulin pen users who injections for type 1 diabetes: Healthcare Compared with Sensor-Augmented received virtual onboarding utilization and A1C Pump Therapy: A Randomized Smith | ePoster Shah | ePoster Crossover Trial Patient Reported Satisfaction During Infusion Set Survival and Performance McAuley | Oral | Sun. 6/27 @ 4:30 pm the Medtronic Extended-Wear During the Medtronic Extended-Wear Infusion Set (EWIS) Pivotal Trial Infusion Set (EWIS) Pivotal Trial Impact of InPen™ smart insulin pen use Brazg | ePoster Buckingham | ePoster on real-world glycemic and insulin Preclinical study of a combined Robust glycemic outcomes after MiniMed™ dosing outcomes in individuals with insulin infusion and glucose sensing Advanced Hybrid Closed-Loop (AHCL) poorly controlled diabetes device (DUO) System use regardless of previous therapy Vigersky | Oral | Sun. 6/27 @ 6:15 pm Zhang | ePoster Shin | ePoster Visit Our Virtual Exhibit https://www.medtronic.com/diabetes-exhibit to find more information on: Smart MDI Therapy Insulin Pump Therapy Personalized Service Stay on Track with the First Automated Insulin Delivery & Support Smart MDI System* for Improved Glucose Control Always By Your Side View Our Presentations Product Theater: Shared Decision With Diabetes Technology Friday, June 25, 2021 | 10:00 – 11:00 am ET The introduction of smart insulin pens is bringing the vast majority of people on insulin injection therapy into the digital age.
    [Show full text]
  • Treatment of Pulmonary Disease of Cystic Fibrosis: a Comprehensive Review
    antibiotics Review Treatment of Pulmonary Disease of Cystic Fibrosis: A Comprehensive Review Rosa María Girón Moreno 1, Marta García-Clemente 2,*, Layla Diab-Cáceres 3, Adrián Martínez-Vergara 4, Miguel Ángel Martínez-García 5 and Rosa Mar Gómez-Punter 1 1 Servicio de Neumología, Instituto de Investigación Sanitaria La Princesa, 28006 Madrid, Spain; [email protected] (R.M.G.M.); [email protected] (R.M.G.-P.) 2 Servicio de Neumología, Hospital Universitario Central de Asturias, C/Avenida de Roma S/n, 33011 Oviedo, Spain 3 Servicio de Neumología, Hospital Universitario 12 de Octubre, 28041 Madrid, Spain; [email protected] 4 Servicio de Neumología, Hospital Universitario de la Princesa, 28006 Madrid, Spain; [email protected] 5 CIBER de Enfermedades Respiratorias, Hospital de la Fe, University of Valencia, 46026 Valencia, Spain; [email protected] * Correspondence: [email protected]; Tel.: +34-985-108000 Abstract: Cystic fibrosis (CF) is a genetic disease that causes absence or dysfunction of a protein named transmembrane conductance regulatory protein (CFTR) that works as an anion channel. As a result, the secretions of the organs where CFTR is expressed are very viscous, so their functionality Citation: Girón Moreno, R.M.; is altered. The main cause of morbidity is due to the involvement of the respiratory system as a García-Clemente, M.; Diab-Cáceres, result of recurrent respiratory infections by different pathogens. In recent decades, survival has been L.; Martínez-Vergara, A.; increasing, rising by around age 50. This is due to the monitoring of patients in multidisciplinary Martínez-García, M.Á.; Gómez-Punter, R.M.
    [Show full text]
  • High-Dose Inhaled Nitric Oxide As Adjunct Therapy in Cystic Fibrosis Targeting Burkholderia Multivorans
    Hindawi Case Reports in Pediatrics Volume 2020, Article ID 1536714, 6 pages https://doi.org/10.1155/2020/1536714 Case Report High-Dose Inhaled Nitric Oxide as Adjunct Therapy in Cystic Fibrosis Targeting Burkholderia multivorans Bethany L. Bartley ,1 Kelly J. Gardner,1,2 Stefano Spina ,3 Bryan P. Hurley,2,4 David Campeau,3 Lorenzo Berra,3,4 Lael M. Yonker,1,2,4 and Ryan W. Carroll 4,5 1Department of Pediatric Pulmonology, Massachusetts General Hospital, 55 Fruit Street, Boston, MA 02114, USA 2%e Mucosal Immunology and Biology Research Center, Massachusetts General Hospital East, 16th Street, Charlestown, MA 02129, USA 3Department of Anesthesia, Massachusetts General Hospital, 55 Fruit Street, Boston, MA 02114, USA 4Harvard Medical School, 25 Shattuck Street, Boston, MA 02115, USA 5Department of Pediatric Critical Care Medicine, Massachusetts General Hospital, 55 Fruit Street, Boston, MA 02114, USA Correspondence should be addressed to Ryan W. Carroll; [email protected] Received 20 January 2020; Revised 15 April 2020; Accepted 30 April 2020; Published 25 June 2020 Academic Editor: Junji Takaya Copyright © 2020 Bethany L. Bartley et al. *is is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Background. Individuals with cystic fibrosis (CF) have persistent lung infections, necessitating the frequent use of antibiotics for pulmonary exacerbations. Some respiratory pathogens have intrinsic resistance to the currently available antibiotics, and any pathogen may acquire resistance over time, posing a challenge to CF care. Gaseous nitric oxide has been shown to have an- timicrobial activity against a wide variety of microorganisms, including common CF pathogens, and offers a potential inhaled antimicrobial therapy.
    [Show full text]
  • Elexacaftor, Tezacaftor, and Ivacaftor | Memorial Sloan Kettering Cancer
    PATIENT & CAREGIVER EDUCATION Elexacaftor, Tezacaftor, and Ivacaftor This information from Lexicomp® explains what you need to know about this medication, including what it’s used for, how to take it, its side effects, and when to call your healthcare provider. Brand Names: US Trikafta Brand Names: Canada Trikafta What is this drug used for? It is used to treat cystic fibrosis. What do I need to tell my doctor BEFORE I take this drug? If you are allergic to this drug; any part of this drug; or any other drugs, foods, or substances. Tell your doctor about the allergy and what signs you had. If you have liver disease. If you take any drugs (prescription or OTC, natural products, vitamins) that must not be taken with this drug, like certain Elexacaftor, Tezacaftor, and Ivacaftor 1/7 drugs that are used for HIV, infections, or seizures. There are many drugs that must not be taken with this drug. This is not a list of all drugs or health problems that interact with this drug. Tell your doctor and pharmacist about all of your drugs (prescription or OTC, natural products, vitamins) and health problems. You must check to make sure that it is safe for you to take this drug with all of your drugs and health problems. Do not start, stop, or change the dose of any drug without checking with your doctor. What are some things I need to know or do while I take this drug? Tell all of your health care providers that you take this drug. This includes your doctors, nurses, pharmacists, and dentists.
    [Show full text]
  • Non-Commercial Use Only
    MRM_01 review.qxp_Hrev_master 19/11/20 17:32 Pagina 48 Multidisciplinary Respiratory Medicine 2020; volume 15:690 REVIEW Novel therapeutic approaches for the management of cystic fibrosis Ryan Jaques, Arslan Shakeel, Cameron Hoyle Centre for Atherothrombosis and Metabolic Disease, Hull York Medical School, University of Hull, UK Cystic fibrosis (CF) is a genetic condition characterised by the build-up of thick, sticky mucus that can damage many of the body’s organs. It is a life-long disease that results in a shortened life expectancy, often due to the progression of advanced lung disease. Treatment has previously targeted the downstream symptoms such as diminished mucus clear- ance and recurrent infection. More recently, significant advances have been made in treating the cause of the disease by targeting the faulty gene responsible. Hope for the development of potential therapies lies with ongoing research into new pharmacological agents and gene therapy. This review gives an overview of CF, and summarises the current evidence regarding the disease management and upcoming strategies aimed at treating or potentially curing this con- dition. only Key words: Cystic fibrosis; CFTR; treatment; infection; gene therapy. use ABSTRACT Non-commercial Correspondence: Ryan Jaques, Molecular Physiology Laboratory, Centre for Atherothrombosis & Metabolic Disease, Hull York Medical School, University of Hull Cottingham Road, Hull HU6 7RX, UK. Tel. +44.1482.465008. E-mail: [email protected] Contributions: RJ, concepted the design of the paper and wrote most of the main text. AS, wrote significant portions of the paper, specifically within the emerging molecular therapies section; he also revised and edited the final draft.
    [Show full text]
  • High Potential Disruption Report May 2020
    PCORI Health Care Horizon Scanning System Volume 2 Issue 1 High Potential Disruption Report May 2020 Prepared for: Patient-Centered Outcomes Research Institute 1828 L St., NW, Suite 900 Washington, DC 20036 Contract No. MSA-HORIZSCAN-ECRI-ENG-2018.7.12 Prepared by: ECRI 5200 Butler Pike Plymouth Meeting, PA 19462 Investigators: Randy Hulshizer, MA, MS Damian Carlson, MS Christian Cuevas, PhD Andrea Druga, PA-C Marcus Lynch, PhD Misha Mehta, MS Brian Wilkinson, MA Donna Beales, MLIS Jennifer De Lurio, MS Eloise DeHaan, BS Eileen Erinoff, MSLIS Madison Kimball, MS Maria Middleton, MPH Diane Robertson, BA Kelley Tipton, MPH Rosemary Walker, MLIS Karen Schoelles, MD, SM Statement of Funding and Purpose This report incorporates data collected during implementation of the Patient-Centered Outcomes Research Institute (PCORI) Health Care Horizon Scanning System, operated by ECRI under contract to PCORI, Washington, DC (Contract No. MSA-HORIZSCAN-ECRI-ENG-2018.7.12). The findings and conclusions in this document are those of the authors, who are responsible for its content. No statement in this report should be construed as an official position of PCORI. An intervention that potentially meets inclusion criteria might not appear in this report simply because the horizon scanning system has not yet detected it or it does not yet meet inclusion criteria outlined in the PCORI Health Care Horizon Scanning System: Horizon Scanning Protocol and Operations Manual. Inclusion or absence of interventions in the horizon scanning reports will change over time as new information is collected; therefore, inclusion or absence should not be construed as either an endorsement or rejection of specific interventions.
    [Show full text]
  • ATC-Index Mit DDD-Angaben Für Deutschland Im Jahr 2020
    Fehler! Kein Text mit angegebener Formatvorlage im Dokument. 1 Uwe Fricke – Judith Günther - Katja Niepraschk- von Dollen – Anette Zawinell Mai 2020 Anatomisch-therapeutisch- chemische Klassifikation mit Tagesdosen für den deutschen Arzneimittelmarkt ATC-Index mit DDD-Angaben GKV-Arzneimittelindex Impressum Die vorliegende Publikation ist ein Beitrag des GKV-Arzneimittelindex im Wissenschaftlichen Institut der AOK (WldO). Anatomisch-therapeutisch-chemische Klassifikation mit Tagesdosen für den deutschen Arzneimittelmarkt ATC-Index mit DDD-Angaben für den deutschen Arzneimittelmarkt Berlin 2020, 19. überarbeitete Auflage Uwe Fricke, Judith Günther, Katja Niepraschk-von Dollen, Anette Zawinell Wissenschaftliches Institut der AOK (WldO) im AOK-Bundesverband GbR Rosenthaler Str. 31, 10178 Berlin Geschäftsführender Vorstand: Martin Litsch (Vorsitzender) Jens Martin Hoyer (stellv. Vorsitzender) http://www.aok-bv.de/impressum/index.html Aufsichtsbehörde: Senatsverwaltung für Gesundheit, Pflege und Gleichstellung –SenGPG– Oranienstraße 106, 10969 Berlin Pharmazeutisch-technische Assistenz: Sandra Heric, Heike Hoffmeister, Sabine Roggan, Manuela Steden Datenverarbeitung: Kenan Ajanovic, Birol Knecht Redaktionelle Bearbeitung: Melanie Hoberg, Manuela Steden Umschlaggestaltung/Design: KomPart Nachdruck, Wiedergabe, Vervielfältigung und Verbreitung (gleich welcher Art), auch von Teilen des Werkes, bedürfen der ausdrücklichen Genehmigung. E-Mail: [email protected] Internet: http://www.wido.de Inhalt Wissenschaftliche Berater des GKV-Arzneimittelindex
    [Show full text]
  • Rescue of Multiple Class II CFTR Mutations by Elexacaftor+Tezacaftor
    ORIGINAL ARTICLE | CYSTIC FIBROSIS Rescue of multiple class II CFTR mutations by elexacaftor+tezacaftor+ ivacaftor mediated in part by the dual activities of elexacaftor as both corrector and potentiator Onofrio Laselva 1,2, Claire Bartlett3, Tarini N.A. Gunawardena1,3, Hong Ouyang3, Paul D.W. Eckford1, Theo J. Moraes3,4, Christine E. Bear1,2,5 and Tanja Gonska3,4 Affiliations: 1Programme in Molecular Medicine, The Hospital for Sick Children, Toronto, ON, Canada. 2Dept of Physiology, University of Toronto, Toronto, ON, Canada. 3Programme in Translational Medicine, The Hospital for Sick Children, Toronto, ON, Canada. 4Dept of Paediatrics, University of Toronto, Toronto, ON, Canada. 5Dept of Biochemistry, University of Toronto, Toronto, ON, Canada. Correspondence: Tanja Gonska, Programme in Translational Medicine, The Hospital for Sick Children, Room 8415, 555 University Avenue, Toronto, ON M5G 8X4, Canada. E-mail: [email protected] @ERSpublications Using pre-clinical studies of F508del in nasal cultures as a benchmark, this study identified other CF mutations for which Trikafta may be clinically effective https://bit.ly/3mbMOqL Cite this article as: Laselva O, Bartlett C, Gunawardena TNA, et al. Rescue of multiple class II CFTR mutations by elexacaftor+tezacaftor+ivacaftor mediated in part by the dual activities of elexacaftor as both corrector and potentiator. Eur Respir J 2021; 57: 2002774 [https://doi.org/10.1183/13993003.02774-2020]. ABSTRACT Positive results in pre-clinical studies of the triple combination of elexacaftor, tezacaftor and ivacaftor, performed in airway epithelial cell cultures obtained from patients harbouring the class II cystic fibrosis transmembrane conductance regulator (CFTR) mutation F508del-CFTR, translated to impressive clinical outcomes for subjects carrying this mutation in clinical trials and approval of Trikafta.
    [Show full text]
  • Research We Fund Handout PDF 302 KB
    Research We Fund Cystic Fibrosis Research The Cystic Fibrosis Foundation is the world’s leader in the fight against CF, and our scientific portfolio reflects our drive to provide effective treatments and -- one day -- a cure to every individual with this disease. We continue to make tremendous progress towards these goals. Last year the U.S. Food and Drug Administration (FDA) expanded the approval of three CFTR modulators, including Trikafta®, using in vitro data to people with certain mutations. It also expanded Kalydeco® to infants as young as four months. However, we will not rest until everyone has a therapy that addresses the underlying cause of their disease. With this commitment in mind, the Foundation launched our Path to a Cure, an ambitious research initiative to accelerate treatments for everyone with CF and ultimately deliver a cure. We intend to allocate a half billion dollars to the effort through 2025 and have already seen an 180% increase in funding for this area of research from 2018. It is also critical to continue to develop new and improved treatments for complications from the disease. We are building on the current momentum, funding an innovative research portfolio and collaborating with top scientists from around the world to deliver the next generation of transformative breakthroughs in CF. To ensure the advancement of potential therapies, we provide research funding and expertise to draw the best scientific minds and technologies into CF. Last year we held more than 230 meetings with over 120 companies – 61 of which were new to CF – and are currently funding nearly 50 different industry programs.
    [Show full text]